• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Adaptive Biotechnologies Corporation

    5/15/26 5:48:36 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADPT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 4)


    Adaptive Biotechnologies Corp

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)




    00650F109

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    00650F109


    1Names of Reporting Persons

    VIKING GLOBAL INVESTORS LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    29,993,708.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    29,993,708.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    29,993,708.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    18.8 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    00650F109


    1Names of Reporting Persons

    VIKING GLOBAL PERFORMANCE LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    22,002,189.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    22,002,189.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    22,002,189.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    13.8 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    00650F109


    1Names of Reporting Persons

    Viking Global Equities II LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    440,046.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    440,046.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    440,046.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.3 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    00650F109


    1Names of Reporting Persons

    Viking Global Equities Master Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    21,562,143.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    21,562,143.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    21,562,143.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    13.5 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    00650F109


    1Names of Reporting Persons

    Viking Long Fund GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,991,519.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,991,519.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,991,519.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    00650F109


    1Names of Reporting Persons

    Viking Long Fund Master Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,991,519.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,991,519.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,991,519.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    00650F109


    1Names of Reporting Persons

    HALVORSEN OLE ANDREAS
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NORWAY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    29,993,708.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    29,993,708.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    29,993,708.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    18.8 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    00650F109


    1Names of Reporting Persons

    Shabet Rose Sharon
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    29,993,708.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    29,993,708.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    29,993,708.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    18.8 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Adaptive Biotechnologies Corp
    (b)Address of issuer's principal executive offices:

    1165 Eastlake Avenue East, Seattle, Washington 98109
    Item 2. 
    (a)Name of person filing:

    Viking Global Investors LP ("VGI"), Viking Global Performance LLC ("VGP"), Viking Global Equities II LP ("VGEII"), Viking Global Equities Master Ltd. ("VGEM"), Viking Long Fund GP LLC ("VLFGP"), Viking Long Fund Master Ltd. ("VLFM"), O. Andreas Halvorsen and Rose S. Shabet (collectively, the "Reporting Persons") Effective March 31, 2026, David C. Ott ("Mr. Ott") retired from his roles as Advisory Director of VGI and Executive Committee Member of each of Viking Global Partners LLC (the general partner of VGI), VGP and VLFGP. Accordingly, this Amendment No. 4 is being filed to remove Mr. Ott as a Reporting Person from this Schedule 13G, as Mr. Ott is no longer a beneficial owner of any of the shares of Common Stock reported herein.
    (b)Address or principal business office or, if none, residence:

    The business address of each of the Reporting Persons is: 600 Washington Boulevard, Floor 11, Stamford, Connecticut 06901.
    (c)Citizenship:

    VGI and VGEII are Delaware limited partnerships; VGP and VLFGP are Delaware limited liability companies; VGEM and VLFM are Cayman Islands exempted companies; O. Andreas Halvorsen is a citizen of Norway; and Rose S. Shabet is a citizen of the United States.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    00650F109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    VGI: 29,993,708 VGI provides managerial services to VGEII, VGEM and VLFM. VGI has the authority to dispose of and vote the shares of Common Stock directly owned by VGEII, VGEM and VLFM. VGI does not directly own any shares of Common Stock. Based on Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act"), VGI may be deemed to beneficially own the shares of Common Stock directly held by VGEII, VGEM and VLFM. VGI beneficially owns 29,993,708 shares of Common Stock consisting of (i) 440,046 shares of Common Stock directly and beneficially owned by VGEII, (ii) 21,562,143 shares of Common Stock directly and beneficially owned by VGEM and (iii) 7,991,519 shares of Common Stock directly and beneficially owned by VLFM. VGP: 22,002,189 VGP, as the general partner of VGEII, has the authority to dispose of and vote the shares of Common Stock directly owned by VGEII. VGP serves as investment manager to VGEM and has the authority to dispose of and vote the shares of Common Stock directly owned by VGEM. VGP does not directly own any shares of Common Stock. Based on Rule 13d-3 of the Act, VGP may be deemed to beneficially own the shares of Common Stock directly held by VGEII and VGEM. VGP beneficially owns 22,002,189 of Common Stock consisting of (i) 440,046 shares of Common Stock directly and beneficially owned by VGEII and (ii) 21,562,143 shares of Common Stock directly and beneficially owned by VGEM. VGEII: 440,046 VGEII has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its general partner, VGP, and by VGI, an affiliate of VGP, which provides managerial services to VGEII. VGEM: 21,562,143 VGEM has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its investment manager, VGP, and by VGI, an affiliate of VGP, which provides managerial services to VGEM. Viking Global Equities LP (a Delaware limited partnership) and Viking Global Equities III Ltd. (a Cayman Islands exempted company), through its investment in VGE III Portfolio Ltd. (a Cayman Islands exempted company), invest substantially all of their assets through VGEM. VLFGP: 7,991,519 VLFGP serves as the investment manager of VLFM and has the authority to dispose of and vote the shares of Common Stock directly owned by VLFM. VLFGP does not directly own any shares of Common Stock. Based on Rule 13d-3 of the Act, VLFGP may be deemed to beneficially own the shares of Common Stock directly held by VLFM. VLFM: 7,991,519 VLFM has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its investment manager, VLFGP, and by VGI, an affiliate of VLFGP, which provides managerial services to VLFM. Viking Long Fund LP (a Delaware limited partnership) and Viking Long Fund III Ltd. (a Cayman Islands exempted company), through its investment in Viking Long Fund Intermediate L.P. (a Cayman Islands limited partnership), invest substantially all of their assets through VLFM. O. Andreas Halvorsen and Rose S. Shabet: 29,993,708 Mr. Halvorsen and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC (general partner of VGI), VGP and VLFGP, have shared authority to dispose of and vote the shares of Common Stock beneficially owned by VGI, VGP and VLFGP. Neither Mr. Halvorsen nor Ms. Shabet directly owns any shares of Common Stock. Based on Rule 13d-3 of the Act, each may be deemed to beneficially own the shares of Common Stock directly held by VGEII, VGEM and VLFM. Mr. Halvorsen and Ms. Shabet each beneficially own 29,993,708 shares of Common Stock, consisting of (i) 440,046 shares of Common Stock directly and beneficially owned by VGEII, (ii) 21,562,143 shares of Common Stock directly and beneficially owned by VGEM and (iii) 7,991,519 shares of Common Stock directly and beneficially owned by VLFM.
    (b)Percent of class:

    The percentages set forth herein are based on 159,697,221 shares of Common Stock outstanding as of March 31, 2026, as reported in the Issuer's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the "Commission") on May 5, 2026. VGI: 18.8% VGP: 13.8% VGEII: 0.3% VGEM: 13.5% VLFGP: 5.0% VLFM: 5.0% O. Andreas Halvorsen and Rose S. Shabet: 18.8%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    VGI: 0 VGP: 0 VGEII: 0 VGEM: 0 VLFGP: 0 VLFM: 0 O. Andreas Halvorsen and Rose S. Shabet: 0

     (ii) Shared power to vote or to direct the vote:

    VGI: 29,993,708 VGP: 22,002,189 VGEII: 440,046 VGEM: 21,562,143 VLFGP: 7,991,519 VLFM: 7,991,519 O. Andreas Halvorsen and Rose S. Shabet: 29,993,708

     (iii) Sole power to dispose or to direct the disposition of:

    VGI: 0 VGP: 0 VGEII: 0 VGEM: 0 VLFGP: 0 VLFM: 0 O. Andreas Halvorsen and Rose S. Shabet: 0

     (iv) Shared power to dispose or to direct the disposition of:

    VGI: 29,993,708 VGP: 22,002,189 VGEII: 440,046 VGEM: 21,562,143 VLFGP: 7,991,519 VLFM: 7,991,519 O. Andreas Halvorsen and Rose S. Shabet: 29,993,708

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The response to Item 4 is incorporated by reference herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    VIKING GLOBAL INVESTORS LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Investors LP (1)(2)
    Date:05/15/2026
     
    VIKING GLOBAL PERFORMANCE LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Performance LLC (1)(2)
    Date:05/15/2026
     
    Viking Global Equities II LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Equities II LP (1)(2)
    Date:05/15/2026
     
    Viking Global Equities Master Ltd.
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Equities Master Ltd. (1)(2)
    Date:05/15/2026
     
    Viking Long Fund GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Long Fund GP LLC (1)(2)
    Date:05/15/2026
     
    Viking Long Fund Master Ltd.
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Long Fund Master Ltd. (1)(2)
    Date:05/15/2026
     
    HALVORSEN OLE ANDREAS
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
    Date:05/15/2026
     
    Shabet Rose Sharon
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Rose S. Shabet (2)
    Date:05/15/2026

    Comments accompanying signature:  (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Ms. Shabet on February 12, 2021 (SEC File No. 005-49737).
    Exhibit Information

    EXHIBIT A - JOINT FILING AGREEMENT

    Get the next $ADPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADPT

    DatePrice TargetRatingAnalyst
    12/2/2025$21.00Equal-Weight
    Morgan Stanley
    9/30/2025$20.00Buy
    Guggenheim
    6/18/2025$15.00Buy
    Craig Hallum
    3/21/2025$9.00Neutral → Buy
    Goldman
    7/5/2023$15.00Overweight
    JP Morgan
    1/5/2023$15.00Sector Outperform
    Scotiabank
    12/21/2022$7.50 → $14.00Neutral → Overweight
    Piper Sandler
    8/25/2022$8.00Underperform
    Credit Suisse
    More analyst ratings

    $ADPT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Adaptive Biotechnologies Corporation

    SCHEDULE 13G/A - Adaptive Biotechnologies Corp (0001478320) (Subject)

    5/15/26 5:48:36 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Adaptive Biotechnologies Corporation

    10-Q - Adaptive Biotechnologies Corp (0001478320) (Filer)

    5/5/26 4:30:44 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adaptive Biotechnologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Adaptive Biotechnologies Corp (0001478320) (Filer)

    5/5/26 4:15:23 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Adaptive Biotechnologies with a new price target

    Morgan Stanley resumed coverage of Adaptive Biotechnologies with a rating of Equal-Weight and set a new price target of $21.00

    12/2/25 8:23:20 AM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Adaptive Biotechnologies with a new price target

    Guggenheim initiated coverage of Adaptive Biotechnologies with a rating of Buy and set a new price target of $20.00

    9/30/25 8:35:50 AM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Craig Hallum initiated coverage on Adaptive Biotechnologies with a new price target

    Craig Hallum initiated coverage of Adaptive Biotechnologies with a rating of Buy and set a new price target of $15.00

    6/18/25 8:08:30 AM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 5, 2021 - Coronavirus (COVID-19) Update: FDA Authorizes Adaptive Biotechnologies T-Detect COVID Test

    For Immediate Release: March 05, 2021 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies. The T-Detect COVID Test is a next generation sequencing based (NGS) test to aid in identifying individuals with an adaptive T cell immune response to SARS-CoV-2, indicating recent or prior infection with SARS-CoV-2.  “Today’s authorization further und

    3/5/21 10:37:33 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Piskel Kyle sold $40,620 worth of shares (3,115 units at $13.04), decreasing direct ownership by 1% to 256,725 units (SEC Form 4) to satisfy tax liability

    4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

    5/20/26 7:13:43 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and COO Rubinstein Julie sold $270,897 worth of shares (19,037 units at $14.23) as part of a pre-agreed trading plan and exercised 14,707 shares at a strike of $8.46, decreasing direct ownership by 1% to 377,802 units (SEC Form 4)

    4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

    4/29/26 7:08:52 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and COO Rubinstein Julie exercised 44,166 shares at a strike of $8.46 and sold $798,423 worth of shares (57,180 units at $13.96) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 382,132 units (SEC Form 4)

    4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

    4/24/26 6:29:47 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

    SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in 33 presentations, including one plenary session and 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 3 in Chicago, and the European Hematology Association (EHA) Congress, taking place June 11-14 in Stockholm. Data at ASCO a

    5/29/26 7:30:00 AM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

    SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences. Craig-Hallum 23rd Annual Institutional Investor Conference – Minneapolis, MNHosting 1x1 meetings on Thursday, May 28thWilliam Blair 46th Annual Growth Stock Conference – Chicago, ILPresentation on Wednesday, June 3rd at 3:20 p.m. Central Time Interested parties may access a live and archived webcast of the presentation from the William Blair Growth Stock Conf

    5/21/26 4:17:30 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

    SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2026. "We delivered strong first quarter results based on accelerating adoption of MRD across both clinical testing and drug development. Our performance reinforces our market leadership position and the differentiated value of our platform," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "With disciplined e

    5/5/26 4:05:00 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    Financials

    Live finance-specific insights

    View All

    Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

    SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2026. "We delivered strong first quarter results based on accelerating adoption of MRD across both clinical testing and drug development. Our performance reinforces our market leadership position and the differentiated value of our platform," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "With disciplined e

    5/5/26 4:05:00 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

    SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, May 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours a

    4/15/26 4:05:00 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

    SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 was an outstanding year for Adaptive, marked by strong execution and meaningful progress across the business," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "We delivered 46% revenue growth and achieved profitability in our MRD business, while advancing our Immune Medici

    2/5/26 4:05:00 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Adaptive Biotechnologies Corporation

    SC 13G - Adaptive Biotechnologies Corp (0001478320) (Subject)

    11/13/24 4:30:24 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Adaptive Biotechnologies Corporation

    SC 13G/A - Adaptive Biotechnologies Corp (0001478320) (Subject)

    11/13/24 9:00:21 AM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Adaptive Biotechnologies Corporation

    SC 13G/A - Adaptive Biotechnologies Corp (0001478320) (Subject)

    11/12/24 1:30:57 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    Leadership Updates

    Live Leadership Updates

    View All

    Grindr Appoints Veteran Public Company CFO and Audit Committee Chair Chad Cohen to Board of Directors

    Cohen to serve as Chair of the Audit Committee Grindr Inc. (NYSE:GRND), the Global Gayborhood in Your Pocket™, today announced the appointment of Chad Cohen, former Chief Financial Officer of Zillow Group Inc. (NASDAQ:Z) and Adaptive Biotechnologies Corp. (NASDAQ:ADPT) and Founding Partner of Scala Advisors, LLC, to Grindr's Board of Directors as of June 3, 2025. Cohen was also appointed to serve as the Chair of Grindr's Audit Committee. A seasoned public company finance executive and board member, Cohen has helped grow several multi-billion dollar technology companies, including multiple leading consumer Internet brands. Prior to his current role, Cohen served as the Chief Financial Of

    6/3/25 4:05:00 PM ET
    $ADPT
    $GRND
    $TRUP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Computer Software: Programming Data Processing
    Technology

    Adaptive Biotechnologies Appoints Tycho Peterson as Chief Financial Officer, Reorganizes and Streamlines Workforce to Drive Growth in Two Key Business Areas

    SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of Tycho Peterson as chief financial officer (CFO). Mr. Peterson brings several decades of financial leadership and experience within the life science and diagnostic industries. "Tycho has been a leader in this space over the last two decades, during which disruptive technologies such as genomic sequencing and artificial intelligence have driven a complete paradigm shift in diagnostics and precision medic

    3/9/22 7:00:00 AM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adaptive Biotechnologies Appoints Nitin Sood as Chief Commercial Officer

    SEATTLE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of Nitin Sood to the newly created position of chief commercial officer, effective immediately. Nitin brings more than 15 years of proven commercial experience at leading life sciences and diagnostics companies, most recently at Guardant Health. "Adaptive has set the stage for commercial success with well-defined growth strategies and a solid pipeline for our current research and diagnostic products. Nit

    8/4/21 4:15:00 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care